Vaccinex, Inc. is a clinical-stage biotechnology company focused on discovery and development of targeted biotherapeutics for neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is a humanized monoclonal antibody targeting SEMA4D, currently in clinical development for Alzheimer's disease, head and neck cancer, and pancreatic cancer. The company also operates the ActivMAb antibody discovery platform and has licensed product candidate CHS-114 to Coherus.
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0000950170-25-054318 | EDGAR | 90K words |
| 2024-04-02 | 2023-12-31 | 0000950170-24-039700 | EDGAR | 85K words |
| 2023-03-31 | 2022-12-31 | 0000950170-23-011354 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001564590-22-012778 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001564590-21-016874 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001564590-20-009251 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007458 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2024-11-14 | 2024-09-30 | 0000950170-24-127139 | EDGAR | 27K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097217 | EDGAR | 26K words |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060603 | EDGAR | 24K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062454 | EDGAR | 21K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042073 | EDGAR | 18K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022252 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037499 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029397 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001564590-22-020252 | EDGAR | — |
| 2021-11-08 | 2021-09-30 | 0001564590-21-055065 | EDGAR | — |
| 2021-08-16 | 2021-06-30 | 0001564590-21-044453 | EDGAR | — |
| 2021-05-17 | 2021-03-31 | 0001564590-21-028189 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-03-19 | 0001193125-25-057850 | EDGAR | 0K words |
| 2025-03-07 | 0001193125-25-049988 | EDGAR | 1K words |
| 2024-12-17 | 0001193125-24-280155 | EDGAR | 1K words |
| 2024-11-14 | 0001193125-24-258757 | EDGAR | 23K words |
| 2024-10-09 | 0001193125-24-235251 | EDGAR | 1K words |
| 2024-09-19 | 0001193125-24-221790 | EDGAR | 11K words |
| 2024-09-13 | 0001193125-24-218870 | EDGAR | 0K words |
| 2024-08-20 | 0001193125-24-203149 | EDGAR | 1K words |
| 2024-08-14 | 0001193125-24-200272 | EDGAR | 2K words |
| 2024-07-31 | 0001193125-24-189569 | EDGAR | 2K words |
143 total filings indexed. 114 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001205922 |
| Ticker | VCNX |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VCNX (~200 tokens, structured JSON with cryptographic provenance)